Relative Bioavailability of Batch 1 and Batch 2 of the Intended Commercial Formulation of BI 425809 Compared to Each Other and to TF 2 Formulation of BI 425809 Following Oral Administration in Healthy Male and Female Subjects (Randomized, Open-label, Single-dose, Three-treatment, Three-period, Six-sequence Crossover Study)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Iclepertin (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 03 Jun 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2019 Planned End Date changed from 25 Apr 2019 to 27 May 2019.
- 01 May 2019 Planned primary completion date changed from 25 Apr 2019 to 27 May 2019.